People · Operator
Named in public records as an officer, director or promoter · active 2015–2025 · Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Absco Therapeutics, Inc. | — | Biotechnology | Series A | $7.0M | $15.2M | 2024 |
| Epharmix, Inc. | — | Other Technology | Seed | $5.0M | $63.9M | 2015 |
Avik Som at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Avik Som on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mark Bakken | 1 | 24 |
| Carlo Giovanni Traverso | 1 | 6 |
| Charles Bolton | 1 | 2 |
| Max Bricklin | 1 | 1 |
| Yiteng Huang | 1 | 1 |
| Blake Marggraff | 1 | 1 |
| Stephen Linderman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.